These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7855695)

  • 1. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
    Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
    Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
    Rodríguez JN; Martino ML; Diéguez JC; Prados D
    Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs.
    Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
    Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
    Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
    Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
    Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
    Qiao ZH
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
    Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.